Short Interest in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Grows By 450.6%

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the target of a large increase in short interest during the month of February. As of February 13th, there was short interest totaling 111,873 shares, an increase of 450.6% from the January 29th total of 20,320 shares. Currently, 6.8% of the company’s shares are short sold. Based on an average daily volume of 293,075 shares, the short-interest ratio is presently 0.4 days. Based on an average daily volume of 293,075 shares, the short-interest ratio is presently 0.4 days. Currently, 6.8% of the company’s shares are short sold.

Catheter Precision Stock Performance

Shares of NYSEAMERICAN VTAK traded up $0.02 during trading on Wednesday, reaching $1.63. The company had a trading volume of 11,500 shares, compared to its average volume of 172,070. The company’s fifty day moving average price is $1.88 and its 200-day moving average price is $2.28. The company has a current ratio of 0.46, a quick ratio of 0.46 and a debt-to-equity ratio of 0.20. Catheter Precision has a 12 month low of $1.14 and a 12 month high of $15.68.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC purchased a new position in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned 2.08% of Catheter Precision as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 20.34% of the company’s stock.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.